1例吉非替尼致Ⅱ级骨髓抑制的病例报告及文献复习

A case report of a grade Ⅱ myelosuppression caused by gefitinib and literature review

摘要:

分析1例EGFR基因突变肺腺癌患者因服用吉非替尼片导致Ⅱ级骨髓抑制的病例，提示临床警惕吉非替尼使用过程中可能出现的骨髓抑制风险，并通过复习相关文献，探讨吉非替尼可能引起的不良反应以及骨髓抑制的治疗方法，为临床用药安全提供参考。

Abstract:

A case of grade Ⅱ myelosuppression caused by gefitinib in a patient of lung adenocarcinoma with EGFR genetic mutation was analyzed here to remind the clinical vigilance against possible risk of myelosuppression during the administration of gefitinib. Meanwhile, by reviewing relevant literature, we also discussed the possible adverse reactions caused by gefitinib and the treatments for myelosuppression, to provide reference for the safety of clinical medication.